Immunome Inc. (IMNM): R&D Expense
$177.29M
Year ended 2025-12-31
$206.23M
Trailing 12 months to 2026-06-30
+96.8%
3-year compound annual growth
+88.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $177.29M | +36.9% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $129.54M | +461.1% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $23.09M | -0.8% | 2025-03-19, From 2023-01-01 |
| 2022-12-31 | $23.27M | +64.9% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $14.11M | +88.5% | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | $7.49M | -15.2% | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | $8.82M | n/a | 2021-03-25, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Immunome Inc. (IMNM) | 2025-12-31 | $177.29M | +36.9% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $90.96M | +78.3% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $25.58M | -30.4% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $300.94M | +43.0% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $65.58M | +3.0% |
| Adagene Inc. (ADAG) | 2025-12-31 | $22.03M | -23.4% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $28.53M | -50.4% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $52.65M | +56.7% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $16.73M | +41.0% |
Compare IMNM, WHWK, OVID, XENE side by side · Screen every company in Pharmaceutical Preparations ↗